A two-injection regimen from Novavax had results on Tuesday. The immune-boosting technology generated antibody levels that were four times higher than people who recovered from the disease. Some participants in the study experienced side effects including fever, headache and fatigue. Early on in the study hospitalizations of patients were misreported, and the vaccine appeared safe in the more than 100 patients who received it. Responses to the shots were about the same throughout the doses, which is good thing because this might make the vaccine easier to produce.
Novavax is located in Gaithersburg, Maryland and they believe another study will be held in the fall. Gregory Glenn, the head of research and development at Novavax said, “We get it, it’s urgent,” but also pointed out that the data on the vaccine candidate needs to be filed with the FDA first before the company can be moved up any earlier.
This is a developing story so be sure to check back regularly for updates at the ABN Blog.